The Cannigma
MAY 13, 2022
There have been a number of preclinical and clinical trials studying cannabis’ effects on pain. The best type of cannabis for dealing with chronic pain tends to be type I or type II strain with a terpene profile that includes linalool, pinene, beta-caryophyllene, limonene, or myrcene. Can topical terpenes alone help with pain?
Cannabis Law Report
OCTOBER 29, 2019
Wakshlag is well-known in the veterinary medicine community as the first doctor to conduct an efficacy study in dogs in a clinical trial at Cornell using ElleVet CBD/CBDA on dogs with multi-joint discomfort. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
JUNE 15, 2021
Charlotte’s story was featured on CNN in 2013 and millions of people saw with their own eyes how a few drops of cannabis oil succeeded where no other epilepsy treatment had —- reducing her seizures from 300 each week to less than three a month. This is of course a given if you’re getting dried flower.
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Fig 1: Sucralose (In Study).
Green Relief
MAY 13, 2018
As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. In 2013, the International Journal of Molecular Science reported on how TBI is affected by diurnal variations of the endocannabinoid system. But CB1 proved to be a tricky target.
Green Relief
MAY 12, 2018
As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. In 2013, the International Journal of Molecular Science reported on how TBI is affected by diurnal variations of the endocannabinoid system. But CB1 proved to be a tricky target.
Cannabis Law Report
JUNE 4, 2021
Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Since founding Eleusis in 2013, Shlomi has overseen the company’s corporate and clinical development efforts. Shlomi Raz.
Expert insights. Personalized for you.
111 
Let's personalize your content